Musculoskeletal Diseases

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Immune System Diseases

Arthritis

Necrosis

Arthritis, Rheumatoid

Joint Diseases

Rheumatic Diseases

Collagen Diseases

Connective Tissue Diseases

Autoimmune Diseases

All Drugs and Chemicals

Pharmaceutical Solutions

Anti-Inflammatory Agents

Antibodies

Antibodies, Monoclonal

Tumor Necrosis Factor Inhibitors

Immunoglobulins

Injections administered at week 0, 2, 4, 6, 8 and 10

Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10

Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10

Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10

Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10

Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10

Placebo solution for injection, administered as subcutaneous injections

Placebo

Olokizumab 60 mg solution for injection, administered as subcutaneous injections

Olokizumab 60 mg

Olokizumab 120 mg solution for injection, administered as subcutaneous injections

Olokizumab 120 mg

Olokizumab 240 mg solution for injection, administered as subcutaneous injections

Olokizumab 240 mg

UCB Clinical Trial Call Center

The primary objective of this study is to evaluate the efficacy and safety of CDP6038 administered subcutaneous (sc) at various doses compared to placebo.

Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy

A Randomized, Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Asian Subjects With Active Rheumatoid Arthritis Having Previously Failed TNF Blocker Therapy

Number of subjects who achieve ACR 20 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

Number of subjects who achieve ACR 50 will be calculated at week 12. The calculation is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

Number of subjects who achieve ACR 70 will be calculated at week 12. The calculations is based on the improvement from the baseline in the number of tender joints and in the number of swollen joints each; and the improvement based on assessments from the patient and the physician drawn according to defined standards.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy	NCT01463059	Rheumatoid Arth...	Placebo Olokizumab 60 m... Olokizumab 120 ... Olokizumab 240 ...	20 Years -	UCB Pharma
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy	NCT01463059	Rheumatoid Arth...	Placebo Olokizumab 60 m... Olokizumab 120 ... Olokizumab 240 ...	20 Years -	UCB Pharma

Spots Global Cancer Trial Database for olokizumab 60 mg